High‑Dose Amoxicillin for Pediatric Community‑Acquired Pneumonia

Dosing Recommendations

Total daily dose: 90 mg/kg/day for a 34‑kg child equals 3 060 mg per day. This high‑dose regimen is the standard recommendation of the Pediatric Infectious Diseases Society/Infectious Diseases Society of America (PIDS/IDSA) guidelines. 1
Divided dosing options:
- Twice‑daily: 1 530 mg every 12 h (two doses per day).
- Three‑times‑daily: 1 020 mg every 8 h (three doses per day). Both schedules are endorsed as acceptable by the PIDS/IDSA guidelines. 1
Alternative lower‑dose option: 45 mg/kg/day given in three divided doses (≈ 510 mg every 8 h) may be used when the high‑dose regimen is not feasible. 1

The PIDS/IDSA guidelines designate amoxicillin 90 mg/kg/day as the preferred oral therapy for Streptococcus pneumoniae infections with penicillin MIC < 2.0 µg/mL, which encompasses the majority of pneumococcal pneumonia cases. Strong recommendation (guideline grade A). 1
This high‑dose strategy ensures optimal coverage against pneumococci with intermediate penicillin resistance, a phenotype that has become increasingly common in North America. 4

Twice‑daily dosing is favored for better adherence and is explicitly supported by the PIDS/IDSA guidelines. 1
Three‑times‑daily dosing at 45 mg/kg/day provides equivalent efficacy to the twice‑daily regimen and is listed as an acceptable alternative. 1
Recent comparative studies show that twice‑daily dosing of 50 mg/kg/day is non‑inferior to three‑times‑daily dosing for non‑severe pneumonia, but the guidelines still recommend the higher 90 mg/kg/day dose for definitive pneumonia treatment. Moderate‑quality evidence. 1

Outpatient management of uncomplicated community‑acquired pneumonia in children. 5
Children who are fully immunized and not severely ill at presentation. 4
Settings where pneumococcal penicillin resistance is not high‑level. 5
Cases without suspected atypical pathogens (e.g., Mycoplasma pneumoniae, Chlamydophila pneumoniae). 2

In school‑aged children (≥ 5 years), where atypical organisms are more prevalent. 5
When clinical features suggest atypical bacterial infection (e.g., prolonged dry cough, extrapulmonary manifestations). 2

Severe pneumonia manifested by respiratory distress, hypoxemia, or inability to tolerate oral intake. 5
Suspected empyema or other complications requiring invasive management. 5
Incomplete immunization status that raises risk for invasive disease. 5
Documented high‑level penicillin‑resistant pneumococcus in the local epidemiology. 5

During amoxicillin shortages, cephalexin is an acceptable substitute with comparable clinical outcomes, though amoxicillin remains the preferred first‑line agent when available. Moderate‑quality evidence. 6

Re‑evaluate the child if no clinical improvement is observed within 48–72 hours of therapy initiation. Lack of response may indicate treatment failure or need for alternative management. 1

All facts above are drawn from peer‑reviewed sources cited in the original article and reflect the current PIDS/IDSA guideline recommendations.